Average Insider

Where insiders trade, we follow

$DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Healthcare
Sector
Medical - Devices
Industry
Gerard J. Michel
CEO
96
Employees
$20.55
Current Price
$328.96M
Market Cap
52W Low$8.12
Current$20.5586.4% above low, 13.6% below high
52W High$22.51

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells12$488,508.0022,500
2 weeksBuys00--All Sells
Sells12$488,508.0022,500
1 monthBuys00--All Sells
Sells12$488,508.0022,500
2 monthsBuys00--All Sells
Sells12$488,508.0022,500
3 monthsBuys00--All Sells
Sells12$488,508.0022,500
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 12, 2026
Martell Bridget A
Director
Sale20,570$21.66$445,546.20View Details
Nov 12, 2026
Martell Bridget A
Director
Sale1,930$22.26$42,961.80View Details
3 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 9, 2026
EPS
Estimated-$0.09
Actual$0.17
Beat
Revenue
Estimated$25.99M
Actual$35.10M
Beat
Nov 3, 2026
EPS
Estimated-$0.10
ActualN/A
Revenue
Estimated$26.00M
ActualN/A
1 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.10.12